Navigation Links
OncoSec Medical Announces $7.2 Million Public Offering
Date:12/13/2012

SAN DIEGO, Dec. 13, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $7.2 million of securities in a registered public offering. OncoSec has agreed to sell to institutional investors an aggregate of 28,800,000 shares of its common stock at $0.25 per share. Additionally, investors will receive warrants to purchase up to 14,400,000 shares of common stock at an exercise price of $0.26 per share for a term of four years.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

The gross proceeds of the offering are expected to be approximately $7.2 million. Net proceeds, after deducting the placement agent's fee and other estimated offering expenses payable by OncoSec, are expected to be approximately $6.5 million.

OncoSec intends to use proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses.

Dawson James Securities, Inc. acted as the exclusive placement agent for the transaction.  Burrill LLC and Noble Financial Capital Markets acted as financial advisors to OncoSec in connection with the transaction.

The offering is expected to close on December 17, 2012, subject to customary closing conditions.

The securities described above are being offered by OncoSec pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission, or the SEC. A prospectus supplement related to the offering will be filed with the SEC. The securities may only be offered by means of a prospectus. Copies of the prospectus and prospectus supplement can be obtained directly from OncoSec and at the
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
8. OncoSec Granted New Patent from China
9. OncoSec to Present at Upcoming Healthcare and Investor Conferences
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... TARRYTOWN, N.Y. , May 21, 2013 ... Inc. (NASDAQ: REGN) today announced that the New ... Phase 2a study results of dupilumab (SAR231893/REGN668) in patients ... antibody targeting the alpha subunit of the interleukin 4 ... and IL-13, drivers of Th2 (Type 2 helper T ...
(Date:5/21/2013)... JUPITER, Fla. , May 21, 2013  BioRestorative ... a life sciences company focused on developing stem cell ... Mark Weinreb , its President and CEO, ... The conference will be held on Thursday, ... at 109 E 42nd Street in New York City.  ...
(Date:5/21/2013)... HENDERSONVILLE, N.C. , May 21, 2013 ... home medical equipment is forcing many small and large ... lay off employees or close their businesses, developments that ... received by Medicare beneficiaries, says the American Association for ... the Centers for Medicare & Medicaid Services ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 2North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 3North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 4
... Newport Corporation (Nasdaq: NEWP ) today announced that it has ... to Dynasil Corporation (OTC Bulletin Board: DYSL), a provider of technology, ... markets. , , ... Hilger, based in Margate, UK, manufactures and sells a variety of ...
... N.Y. , July 20 As of ... standards applicable to devices that measure A1C (or glycated ... (NGSP) changed to +/-0.75% A1C, 95% CI, 4-10.0% A1C ... SELFCHECK devices, submits for annual NGSP certification each June ...
Cached Medicine Technology:Newport Corporation Completes Sale of Hilger Crystals to Dynasil Corporation 2Newport Corporation Completes Sale of Hilger Crystals to Dynasil Corporation 3New Standard of National Glycohemoglobin Standardization Program 2New Standard of National Glycohemoglobin Standardization Program 3
(Date:5/21/2013)... NY (PRWEB) May 21, 2013 Two-thirds ... or non-small cell lung cancer reported that they engage ... their medicine use, according to new findings from the ... by Kantar Health . The research will be ... ISPOR (International Society for Pharmacoeconomics and Outcomes Research) in ...
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 ... was voted #1 for plastic surgery SEO services ... respondents were asked to name the “Best Plastic ... services say the outcome was predictable. Well-known in ... identified more by patients than any other selection ...
(Date:5/21/2013)... 2013 It’s nearly summer and millions of ... starting practice for summer or fall sports. In many ... activities can begin. , To help parents during this ... sports or camp physicals at just $29. ... a child’s medical history, perform a physical exam and complete ...
(Date:5/21/2013)... Nearly 40 Platinum Supplemental Insurance Sales Representatives and ... Cabos, Mexico, Feb. 23-March 1, 2013, to help renovate Casa ... facility serves meals and provides a social outlet for 45 ... Platinum Vice President, Mike Muench, says that the idea for ... “Platinum got its start selling long-term care insurance ,” ...
(Date:5/21/2013)... 2013 Access MediQuip, LLC , ... company, announced today that it has expanded its national ... nation's largest health benefits companies, with more than 36 ... 66 million individuals served through its subsidiaries. , WellPoint ... implant management program agreement back in 2008. Under the ...
Breaking Medicine News(10 mins):Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 2Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 3Health News:JD Media Surge's CosmeticSurgeonsOnline.com Voted #1 Source for Plastic Surgery SEO 2Health News:MedSpring Offers Camp and Sports Physicals For $29 2Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 2Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 3Health News:Access MediQuip and WellPoint Renew and Expand National Contract for Implantable Medical Devices 2Health News:Access MediQuip and WellPoint Renew and Expand National Contract for Implantable Medical Devices 3
... results from a large-scale study of key antimalarial medicines ... percentage of medicines circulating on national markets are of ... of drug-resistant strains of Plasmodium falciparum , the ... by the Promoting the Quality of Medicines (PQM) Program, ...
... of advanced breast cancer diagnosis among black women remained ... women between 1992 and 2004, according to new findings ... addition, the disparity in the incidence of advance colorectal ... fell among whites but increased slightly among blacks. , ...
... ... significant achievement and differentiates Hallmark Insights from its peers in the incentive services ... (PRWEB) ... that it has successfully completed a Statement on Auditing Standards (SAS) 70 Type II ...
... Small study reports improvement in thinking skills, , ... drug may improve thinking, learning and memory skills ... disorder, new research says. , Huntington,s affects movement, ... disease usually die within 10 to 30 years ...
... brass support improved school nutrition to cut obesity, ensure qualified recruits ... Johnnie E. Wilson , U.S. Army (Ret.), and Lieutenant General ... preventing child obesity is a matter of national security, noting that ... are unable to enlist in the armed services. The generals, comments ...
... , Feb. 9 The National ... join the Commission on Cancer (CoC), a multidisciplinary organization administered ... morbidity and mortality of cancer through education, standards setting, and ... has invited NCCS, a key patient advocacy organization, to join ...
Cached Medicine News:Health News:One-third of antimalarial medicines sampled in 3 African nations found to be substandard 2Health News:One-third of antimalarial medicines sampled in 3 African nations found to be substandard 3Health News:Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S. 2Health News:Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S. 3Health News:Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S. 4Health News:Hallmark Insights Completes SAS 70 Type II Audit 2Health News:Drug May Ease Cognitive Effects of Huntington's 2Health News:Retired Military Brass Support First Lady's Call to Reduce Child Obesity, Improve Nutrition 2Health News:The National Coalition for Cancer Survivorship Joins the Commission on Cancer 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: